Search Results

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Gain Therapeutics, Inc. announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open.

Gain Therapeutics, Inc. announced the pricing of an underwritten public offering of 7,116,547 shares of its common stock at a public offering price of $1.35 per share and pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024.

Gain Therapeutics, Inc. today announces the presentation of a poster at the Federation of European Neuroscience Societies (FENS) Forum 2024.

Gain Therapeutics, Inc., a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, reports financial results for the quarter ended March 31, 2024, and provides a corporate update.